Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4144590 | 1.00 | SLC6A3 (0.56) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL7457828 | 0.87 | SLC6A3 (0.70) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL7457834 | 0.87 | SLC6A3 (0.70) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL7457839 | 0.87 | SLC6A3 (0.70) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5731527 | 0.85 | SLC6A3 (0.56) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL13752147 | 0.85 | SLC6A3 (0.56) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL7664902 | 0.83 | SLC6A3 (0.60) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL7353829 | 0.81 | SLC6A3 (0.57) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL7358586 | 0.81 | SLC6A3 (0.57) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL7358592 | 0.81 | SLC6A3 (0.57) | SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090208415-A1 | Tropane compounds | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-08-20 | — | — | US | disclosed |
| US-7476740-B2 | Monoamine transporter inhibitors; used for early diagnosis and treatment of neurological and psychiatric conditions | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-01-13 | — | — | US | disclosed |
| EP-1483237-A4 | TROPANE COMPOUNDS | HARVARD COLLEGE (US) | 2006-07-05 | — | — | EP | disclosed |
| EP-1483237-A2 | TROPANE COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20030232819-A1 | Tropane compounds | WILMINGTON TRUST (LONDON) LIMITED, AS SECURITY AGENT (GB) | 2003-12-18 | — | — | US | disclosed |
| WO-2003099783-A2 | TROPANE COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232819-A1 | Tropane compounds | TPM3, TPM4, ADRA2C | SLC6A3 196/4885SLC6A2 93/4885SLC6A4 217/4885 |
| US-20090208415-A1 | Tropane compounds | TPM3, TPM4, ADRA2C | SLC6A3 196/4885SLC6A2 93/4885SLC6A4 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.